Successful Outcomes Using Combination Therapy of Interleukin-2 and Interferon-α for Renal Cell Carcinoma Patients with Lung Metastasis

被引:22
|
作者
Akaza, Hideyuki [1 ]
Kawai, Koji [1 ]
Tsukamoto, Taiji [2 ]
Fujioka, Tomoaki [3 ]
Tomita, Yoshihiko [4 ]
Kitamura, Tadaichi [5 ]
Ozono, Seiichiro [6 ]
Miki, Tsuneharu [7 ]
Naito, Seiji [8 ]
Zembutsu, Hitoshi [9 ,10 ]
Nakamura, Yusuke [9 ,10 ]
机构
[1] Univ Tsukuba, Dept Urol & Androl, Grad Sch Comprehens Human Sci, Tsukuba, Ibaragi 3058576, Japan
[2] Sapporo Med Univ, Sch Med, Dept Urol Surg & Androl, Sapporo, Hokkaido, Japan
[3] Iwate Med Univ, Sch Med, Dept Urol, Morioka, Iwate 020, Japan
[4] Yamagata Univ, Fac Med, Dept Urol, Yamagata 990, Japan
[5] Univ Tokyo, Fac Med, Dept Urol, Tokyo 113, Japan
[6] Hamamatsu Univ Sch Med, Dept Urol, Shizuoka, Japan
[7] Kyoto Prefectural Univ Med, Dept Urol, Kyoto, Japan
[8] Kyushu Univ, Grad Sch Med Sci, Dept Urol, Fukuoka 812, Japan
[9] Univ Tokyo, Mol Med Lab, Inst Med Sci, Ctr Human Genome, Tokyo 1138654, Japan
[10] Univ Tokyo, Lab Genome Technol, Inst Med Sci, Ctr Human Genome, Tokyo 1138654, Japan
关键词
renal cell carcinoma; interleukin-2; interferon-alpha; cytokine; combination therapy; lung metastasis; HIGH-DOSE INTERLEUKIN-2; KIDNEY CANCER; IMMUNOTHERAPY; SURVIVAL; SUNITINIB; TRIAL;
D O I
10.1093/jjco/hyq027
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In our previous study, a combination therapy of interleukin-2 and interferon-alpha was found to be more effective than monotherapy, especially for lung metastasis. In order to determine the genetic markers of those who positively responded, a multi-institutional open study was conducted on the patients with lung metastasis. In this paper, the clinical response to our combination therapy is reported. Untreated patients with lung metastasis were enrolled in this study. Patients received interleukin-2 (0.7 x 10(6) U/day) and interferon-alpha (6 x 10(6) IU/day): interleukin-2, 5 days a week and interferon-alpha, 3 days a week for the first 8 weeks, and then both interleukin-2 and interferon-alpha, 2 or 3 days a week for 16 additional weeks. Forty-two patients were able to be evaluated for response. The overall positive response rate was 35.7% (15 of 42) including 2 patients with complete response. Progression-free patients were observed more frequently in patients with lung metastasis only (80.6%) than those with lung plus other organ metastasis (54.5%). Tumor shrinkage was observed in 81.0% (34 of 42) of patients. Progression-free survival rate at 200 days was 63.6%. Toxicities observed were primarily flu-like symptoms due to the cytokines and were typical of those observed with each single agent. Combination therapy of interleukin-2 and interferon-alpha was confirmed to be effective for renal cell carcinoma patients with lung metastasis. Identification of genetic markers is now ongoing with the tissue samples from this trial.
引用
收藏
页码:684 / 689
页数:6
相关论文
共 50 条
  • [1] A low-dose combination therapy of interleukin-2 and interferon-α is effective for lung metastasis of renal cell carcinoma: A multicenter open study
    Akaza H.
    Tsukamoto T.
    Onishi T.
    Miki T.
    Kinouchi T.
    Naito S.
    International Journal of Clinical Oncology, 2006, 11 (6) : 434 - 440
  • [3] Progressive anemia following combination therapy with interferon-α and interleukin-2 in a patient with metastatic renal cell carcinoma
    Hosokawa, Y
    Kishino, T
    Ono, T
    Oyama, N
    Hayashi, K
    Momose, H
    INTERNATIONAL JOURNAL OF UROLOGY, 2004, 11 (10) : 906 - 908
  • [4] Interleukin-2, interferon-α and interleukin-2 plus interferon-α in renal cell carcinoma.: A randomized phase II trial
    Boccardo, F
    Rubagotti, A
    Canobbio, L
    Galligioni, E
    Sorio, R
    Lucenti, A
    Cognetti, F
    Ruggeri, E
    Landonio, G
    Baiocchi, C
    Besana, C
    Citterio, G
    De Rosa, M
    Calabresi, F
    TUMORI, 1998, 84 (05) : 534 - 539
  • [5] Interleukin-2, interferon-α and medroxyprogesterone acetate in metastatic renal cell carcinoma
    Naglieri, E
    Lopez, M
    Lelli, G
    Morelli, F
    Amodio, A
    Di Tonno, P
    Gebbia, N
    Di Seri, M
    Chetri, MC
    Rizzo, P
    Abbate, I
    Casamassima, A
    Selvaggi, FP
    Colucci, G
    ANTICANCER RESEARCH, 2002, 22 (05) : 3045 - 3051
  • [6] Metastasis renal cell carcinoma:: Therapy alternative to interferon-α
    Staehler, Michael
    AKTUELLE UROLOGIE, 2008, 39 (02) : 92 - +
  • [7] INTERLEUKIN-2 AND INTERFERON IN RENAL-CELL CARCINOMA
    WERSALL, P
    MEDICAL ONCOLOGY AND TUMOR PHARMACOTHERAPY, 1993, 10 (1-2): : 71 - 76
  • [8] COMBINATION OF INTERLEUKIN-2 AND GAMMA-INTERFERON IN METASTATIC RENAL-CELL CARCINOMA
    ESCUDIER, B
    FARACE, F
    ANGEVIN, E
    TRIEBEL, F
    ANTOUN, S
    LECLERCQ, B
    BRANDELY, M
    ABOUDARAM, A
    NITENBERG, G
    HERCEND, T
    EUROPEAN JOURNAL OF CANCER, 1993, 29A (05) : 724 - 728
  • [9] A case of renal cell carcinoma with multiple lung metastases refractory to interferon-α showing complete remission by interleukin-2 monotherapy
    Hayashi, Tetsuya
    Miyagawa, Yasushi
    Tsujimura, Akira
    Nonomura, Norio
    Minami, Masato
    Okuyama, Akihiko
    INTERNATIONAL JOURNAL OF UROLOGY, 2006, 13 (06) : 805 - 808
  • [10] Delirium after interleukin-2 and alpha-interferon therapy for renal cell carcinoma
    Van Steijn, JHM
    Nieboer, P
    Hospers, GAP
    De Vries, EGE
    Mulder, NH
    ANTICANCER RESEARCH, 2001, 21 (05) : 3699 - 3700